Business Context and Reporting Period
Tango Therapeutics, Inc. (TNGX), a Delaware corporation, filed this Form 8-K on August 10, 2023, to report the entry into a Material Definitive Agreement. The Company is an emerging growth company focused on developing therapies, with principal executive offices in Boston, MA.
Key Financial Metrics and Transaction Details
This filing details a private placement of equity securities rather than periodic financial performance metrics. Key transaction figures include:
- Common Stock Issued: 13,196,671 shares at $5.15 per share.
- Pre-Funded Warrants Issued: 2,340,579 warrants to purchase Common Stock at $5.1499 per warrant.
- Aggregate Gross Proceeds: Approximately $80 million (before deducting offering commissions and expenses).
- Anticipated Closing Date: August 11, 2023.
The filing does not provide current revenue, profit, cash flow, margins, or debt levels. The Company is not generating revenue from product sales as it is a pre-commercial biopharmaceutical entity.
Material Changes and Agreements
The primary material change is the execution of a Securities Purchase Agreement for the private placement described above. Additional material terms include:
- Registration Rights: The Company agreed to file a registration statement with the SEC by September 1, 2023, to register the resale of the shares and warrant shares, keeping it effective for up to three years.
- Lock-Up Agreements: Directors and executive officers entered into 90-day lock-up agreements, restricting the disposal of their existing shares and securities, subject to customary exceptions.
- Beneficial Ownership Limits: Holders of Pre-Funded Warrants are restricted from exercising if it would result in beneficial ownership exceeding 9.99% of outstanding shares, though this can be increased to 19.99% with 61 days' prior notice.
Outlook, Risks, and Contingencies
The Company anticipates the closing of the Private Placement on August 11, 2023, subject to customary closing conditions. The proceeds are intended to fund the Company's operations and clinical development programs, though specific allocation details are not provided in this text.
Risks and Forward-Looking Statements: The filing contains forward-looking statements regarding the expected closing and proceeds. Actual results may differ due to risks detailed in the Company's Form 10-K for the period ended December 31, 2022, and subsequent Form 10-Q filings. The transaction is exempt from registration under Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D.
Investor Verification Checklist
- Verify the actual closing of the Private Placement on or after August 11, 2023.
- Confirm the filing of the registration statement for resale of securities by September 1, 2023.
- Review the definitive Securities Purchase Agreement (Exhibit 10.1) for specific covenants and indemnification terms.
- Monitor subsequent filings for the use of the approximately $80 million in gross proceeds.
- Check for any updates to the Company's cash runway and burn rate in the next quarterly report.